LAPTM4B基因多态性与肺癌易感性的关系

目的:探讨溶酶体相关4次跨膜蛋白质β(lysosome-associated protein transmembrane4 beta,LAPTM4B)基因多态性与肺癌易感性的关系.方法:以病例-对照研究的方法,用基于特异性引物的PCR对134例正常人和162例肺癌患者进行LAPTM4B基因分型,将卡方检验用于检测肺癌组和对照组基因型频率和其它参数的分布.结果:LAPTM4B的*2等位基因频率在肺癌组中为40.1%,较对照组(28.0%)显著增高(P=0.002).基因型分布在肺癌组和对照组间差异有统计学意义.*1/2和*2/2基因携带者患肺癌的危险性分别是*1/1的1.91倍(95%CI:1.178～3.110)与3.26倍(95%CI:1.338～7.929).LAPTM4B基因型分布与患者年龄,肺癌的病理类型,分化程度,临床分期以及HBV感染等无明显关系.结论:LAPTM4B基因多态性与肺癌易感性相关,* 2等位基因可能是肺癌发生的危险因素.

Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer

OBJECTIVE: To investigate the possible association between the allelic variation of LAPTM4B and the genetic susceptibility of lung cancer. METHODS: The genotype of LAPTM4B was analyzed in 134 unrelated healthy adult individuals and 166 patients with lung cancer by utilizing polymerase chain reaction based on special primers. The genotypical distribution of LAPTM4B was analyzed by chi2 test. RESULTS: The allelic frequencies of the *2 were 40.1% and 28.0% in the lung cancer group and the healthy control group respectively, which was significantly different between the two groups (P=0.002). There was a significant difference in the overall genotypical distribution between the patients and the controls (P=0.005). The risk of suffering from lung cancer was increased 1.91 times in the individuals of the *1/2 genotype (95%CI: 1.178-3.110) and 3.26 times in the individuals of the *2/2 genotype of LAPTM4B (95%CI: 1.338-7.929) compared with the *1/2 genotype. No association was observed between the genotypical distribution of LAPTM4B and the clinical information on patients of lung cancer such as gender, age, pathological type, differentiation classification of TNM and infection of HBV. CONCLUSION: This study suggests that the allele *2 of LAPTM4B might be the risk factor of lung cancer, which could be associated with genetic susceptibility of lung cancer.